Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 2010

View Archived Issues

Roche claims new tachykinin NK3 receptor antagonists

Genz-123346 inhibits cystogenesis in models of polycystic kidney disease

GSK identifies new macrolide inhibitors of IL-6 production

Karus Therapeutics presents new HDAC inhibitors

Emory University discloses new NMDA receptor antagonists

Potentiometric detection of membrane-bound sialic acid shows promise to diagnose cancer

Hyperglycemia correlates with low SHBG levels in androgenetic alopecia

Combination of first-line bevacizumab and chemotherapy is safe in NSCLC

SNPs in IL17RA and IL17A genes may associate with alopecia areata phenotype

Advaxis completes dosing initial group in phase II ADXS11-001 trial in cervical dysplasia

Rush University Medical Center participates in phase II MGAWN1 trial in West Nile virus infection

Curaxis provides update on Memryte development for Alzheimer's disease

Evotec Neurosciences presents new histamine H3 receptor antagonists

EMA accepts Optimer Pharma's fidaxomicin MAA for review

FDA grants priority review for Benlysta BLA in SLE

U.S. scientists identify new cromolyn derivatives

Chelsea Therapeutics' droxidopa enters phase II trial in chronic fatigue syndrome

FDA grants orphan drug status to ACE-031 for Duchenne's muscular dystrophy

FDA advisory committee recommends expanding pain indications for Cymbalta

SRI International and Taiho furthering development of TAS-108 for breast cancer

Reconstituted HDL suppresses inflammation-induced angiogenesis in vitro

Cellmid's midkine-directed antibodies CDY-91 and CDY-92 reduce disease severity in MS model

Vertex Pharma provides update on recent clinical developments

Celgene receives marketing authorization in Japan for Revlimid

University of Pittsburgh receives NCI grant to develop agents for head and neck cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...